Vicriviroc: Anti-HIV agent viral entry inhibitor chemokine CCR5 antagonist

Drugs of the Future

Volumn 32, Issue 5, 2007, Pages 417-427

  Revill, P ^a   Bayes M ^a   Bozzo, J ^a   Serradell, N ^a   Rosa, E ^a   Bolos J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; EFAVIRENZ; ENFUVIRTIDE; GLYCOPROTEIN P INHIBITOR; HGS 004; INCB 15050; INCB 9471; INDINAVIR; KD 274; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; PF 232798; PLACEBO; PRO 140; RITONAVIR; SAQUINAVIR; SP 01A; TENOFOVIR; TNX 355; UNCLASSIFIED DRUG; VICRIVIROC; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS;

EID: 34547784619     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.05.1100315     Document Type: Article

References (51)

1. Baroudy, B.M., Clader, J.W., Gilbert, E. et al. (Schering Corp.). Piperazine derivs. useful as CCR5 antagonists. CA 2371583, EP 1632479, JP 2002543185, JP 2006052225, WO 0066558.
2. Baroudy, B.M., Clader, J.W., Josien, H.B. et al. (Schering Corp.). Piperazine derivatives useful as CCR5 antagonists. US 2003069252, US 6689765.
3. Baroudy, B.M., Clader, J.W., Josien. H.B. et al. (Schering Corp.). Piperazine derivatives useful as CCR5 antagonists. US 6391865.
4. Tagat, J.R., McCombie, S.W., Nazareno, D. et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5- pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S) -methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem 2004, 47(10): 2405-8.
5. Kuo, S.-C., Tsai, D.J.-S., Liao, H. (Schering Corp.). Preparation of ketone amides. WO 2006247437, WO 2006074264.
6. Leong, W., Chen, M., Sa Bosco, D. et al. (Schering Corp.). Synthesis of piperidine and piperazine compounds as CCR5 antagonists. JP 2005521743, US 2004024217, US 6992189, WO 03084950.
7. Mocroft, A., Vella, S., Benfield, T.L. et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998, 352(9142): 1725-30.
8. Palella, F.J., Delaney, K.M., Moorman, A.C. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338(13): 853-60.
9. Struble, K., Murray, J., Cheng, B., Gegeny, T., Miller, V., Gulick, R. Antiretroviral therapies for treatment-experienced patients: Current status and research challenges. AIDS 2005, 19(8): 747-56.
10. Idemyor, V. Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: Are they the next novel therapies? HIV Clin Trials 2005, 6(5): 272-7.
11. Poveda, E., Briz, V., Quinones-Mateu, M., Soriano, V. HIV tropism: Diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006, 20(10): 1359-67.
12. Lederman, M.M., Penn-Nicholson, A., Cho, M., Mosier, D. Biology of CCR5 and its role in HIV infection and treatment. JAMA - J Am Med Assoc 2006, 296(7): 815-26.
13. Westby, M., van der Ryst, E. CCR5 antagonists: Host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 2005, 16(6): 339-54.
14. Gonsiorek, W., Strizki, J., Hesk, D., Lundell, D., Hipkin, R.W. Analysis of CCR5 binding kinetics and coupling states reveals distinct binding properties of small molecule CCR5 antagonists. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst H-243.
15. Strizki, J.M., Tremblay, C., Xu, S. et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005, 49(12): 4911-9.
16. Murga, J.D., Franti, M., Pevear, D.C., Maddon, P.J., Olson, W.C. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2006, 50(10): 3289-96.
17. Wojcik, L., Gheyas, F., Ogert, R., Strizki, J. In vitro anti-HIV-1 activity of SCH 417690 in combination with other antiretroviral therapies and against resistant HIV-1 strains. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst H-1096.
18. Chen, Z., Hu, B., Huang, W. et al. HIV-1 mutants less susceptible to SCH-D, a novel small-molecule antagonist of CCR5. 9th Conf Retroviruses Opportunistic Infect (CROI) (Feb 24-28, Seattle) 2002, Abst 396-T.
19. Marozsan, A.J., Kuhmann, S.E., Morgan, T. et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005, 338(1): 182-99.
20. Pugach, P., Marozsan, A.J., Ketas, T.J., Landes, E.L., Moore, J.P., Kuhmann, S.E. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007, 361(1): 212-28.
21. Strizki, J., Wojcik, L., Marozsan, A.J. et al. Properties of in vitro generated HIV-1 variants resistant to the CCR5 antagonists SCH 351125 and SCH 417690. Antivir Ther [14th Int HIV Drug Resist Workshop: Basic Princ Clin Implic (June 7-11, Quebec) 2005] 2005, 10(4, Suppl.): S66.
22. Knemeyer, I., Crossman, L., Wirth, M. Vicriviroc (SCH 417690) distribution from the gut to gut-associated lymphoid tissues (GALT) and to peripheral lymphoid tissues following an oral dose. Retrovirology [Int Meet Inst Hum Virol (Aug 29-Sept 2, Baltimore) 2005] 2005, 2(Suppl. 1): Abst P115.
23. Divirgilio, D., Grubb, N., Keung, A., Srnka, A. Distribution of drug-derived material into milk and transfer via milk to pups after oral administration of 14C-SCH 417690 to rats. Annu Meet Am Assoc Pharm Sci (AAPS) (Nov 6-10, Nashville) 2005, Abst T2302.
24. Ghosal, A., Barecki-Roach, M., Ramanathan, R., Yuan, Y., Casciano, C. Characterization of the in vitro human liver cytochrome P450 (CYP) mediated metabolism and inhibition potential of vicriviroc. Retrovirology [Int Meet Inst Hum Virol (Aug 29-Sept 2, Baltimore) 2005] 2005, 2(Suppl. 1): Abst P116.
25. Ramanathan, R., Zhong, R., Alvarez, N. et al. Comparative metabolism and excretion of a novel CCR5 receptor antagonist, SCH 417690 (vicriviroc), in human, monkey and rat. 13th North Am Int Soc Study Xenobiot (Oct 23-27, Maui) 2005, Abst 403.
26. Keung, A., Sansone, A., Caceres, M., Kraan, M., Gaillac, B. Effect of food on bioavailability of SCH 417690 in healthy volunteers. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst A-1200.
27. Sansone, A., Keung, A., Caceres, M., Kraan, M., Rouzier, R. Rising multiple-dose assessment of Sch 417690 - Similar safety, tolerability, and pharmacokinetics (pk) in uninfected and HIV-infected adults. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst A-33.
28. Sansone, A., Kraan, M., Long, J. QTc interval analysis of SCH 417690, a novel CCR5 inhibitor. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst H-1095.
29. Keung, A., Prasad, P., Martinho, M. et al. A pharmacokinetic- pharmacodynamic (PK-PD) disease model to describe antiviral activity of vicriviroc (VCV). 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-387.
30. Schuermann, D., Rouzier, R., Nougarede, R. et al. SCH D: Antiviral activity of a CCR5 receptor antagonist. 11th Conf Retroviruses Opportunistic Infect (CROI) (Feb 8-11, San Francisco) 2004, Abst 140LB.
31. Schuermann, D., Pechardscheck, C., Rouzier, R. et al. SCH 417690: Antiviral activity of a potent new CCR5 receptor antagonist. 3rd IAS Conf HIV Pathog Treat (July 24-27, Rio de Janeiro) 2005, Abst TuOa0205.
32. Greaves, W., Landovitz, R., Fatkenheuer, G. et al. Late virologic breakthrough in treatment-naive patients on a regimen of Combivir + vicriviroc. 13th Conf Retroviruses Opportunistic Infect (CROI) (Feb 5-9, Denver) 2006, Abst 161LB.
33. Landovitz, R., Fatkenheuer, G., Hoffmann, C. et al. Characterization of susceptibility profiles for the CCR5 antagonist vicriviroc in treatment-naive HIV-infected subjects. Antivir Ther [15th Int HIV Drug Resist Workshop: Basic Princ Clin Implic (June 13-17, Sitges) 2006] 2006, 11(5, Suppl.): S23.
34. Safety and effectiveness of the oral HIV entry inhibitor vicriviroc in HIV infected patients (NCT00082498). ClinicalTrials.gov Web site, May 15, 2007.
35. Gulick, R.M., Su, Z., Flexner, C. et al. ACTG 5211: Phase II study of the safety and efficacy of vicriviroc in HIV-infected treatment-experienced subjects. 16th Int AIDS Conf (Aug 13-18, Toronto) 2006, Abst THLB0217.
36. Vicriviroc (SCH 417690) in combination treatment with optimized ART regimen in experienced subjects (VICTOR-E1) (Study P03672AM3) (NCT00243230). ClinicalTrials.gov Web site, May 15, 2007.
37. Vicriviroc, a CCR5 inhibitor, added to an optimized antiretroviral therapy for previously treated HIV (VICTOR-E2) (Study P04285) (terminated) (NCT00243568). ClinicalTrials.gov Web site, May 15, 2007.
38. Vicriviroc to be studied in combination with an optimized antiretroviral regimen offered to HIV-treatment experienced subjects (Study P04889) (NCT00474370). ClinicalTrials.gov Web site, May 15, 2007.
39. Li, C., Keung, A., Morrison, R.A., White, R.E. Vicriviroc, a novel CCR5 inhibitor, is not a p-glycoprotein substrate in vitro. Retrovirology [Int Meet Inst Hum Virol (Aug 29-Sept 2, Baltimore) 2005] 2005, 2(Suppl. 1): Abst P158.
40. Sansone, A., Seiberling, M., Kraan, M., Keung, A., Martinho, M. Similar increase in SCH 417690 plasma exposure with coadministration of varying doses of ritonavir in healthy volunteers. 6th Int Workshop Clin Pharmacol HIV Ther (April 28-30, Quebec) 2005, Abst 78.
41. Seiberling, M., Kraan, M., Keung, A., Martinho, M., Sansone, A. Similar increase in SCH 417690 plasma exposure with coadministration of varying doses of ritonavir in healthy volunteers. 3rd IAS Conf HIV Pathog Treat (July 24-27, Rio de Janeiro) 2005, Abst TuPe3. 1B06.
42. Saltzman, M., Rosenberg, M., Kraan, M., Keung, A., Boutros, T., Sansone, A. Pharmacokinetics of SCH 417690 administered alone or in combination with ritonavir or lopinavir/ritonavir. 3rd IAS Conf HIV Pathog Treat (July 24-27, Rio de Janeiro) 2005, Abst TuPe3.1B05.
43. Sansone, A., Saltzman, M., Rosenberg, M., Kraan, M., Keung, A., Boutros, T. Pharmacokinetics of SCH 417690 administered alone or in combination with ritonavir or lopinavir/ritonavir. 6th Int Workshop Clin Pharmacol HIV Ther (April 28-30, Quebec) 2005, Abst 83.
44. Guillaume, M., Kraan, M., Soni, P., Keung, A., Sansone, A. Pharmacokinetics of SCH 417690 administered alone or in combination with tenofovir. 3rd IAS Conf HIV Pathog Treat (July 24-27, Rio de Janeiro) 2005, Abst TuPe3.1B09.
45. Sansone, A., Guillaume, M., Kraan, M., Soni, P., Keung, A., Boutros, T. Pharmacokinetics of SCH 417690 administered alone or in combination with tenofovir. 6th Int Workshop Clin Pharmacol HIV Ther (April 28-30, Quebec) 2005, Abst 85.
46. Saltzman, M., Rosenberg, M., Kraan, M. et al. Pharmacokinetics of SCH 417690 administered alone or in combination with ritonavir and efavirenz in healthy volunteers. 3rd IAS Conf HIV Pathog Treat (July 24-27, Rio de Janeiro) 2005, Abst TuPe3.1B08.
47. Sansone, A., Saltzman, M., Rosenberg, M. et al. Pharmacokinetics of SCH 417690 administered alone or in combination with ritonavir and efavirenz in healthy volunteers. 6th Int Workshop Clin Pharmacol HIV Ther (April 28-30, Quebec) 2005, Abst 79.
48. Guillaume, M., Kraan, M., Keung, A., Caceres, M., Sansone, A. The pharmacokinetics of SCH 417690 when administered alone and in combination with lamivudine/zidovudine. 3rd IAS Conf HIV Pathog Treat (July 24-27, Rio de Janeiro) 2005, Abst TuPe3.1B03.
49. Sansone, A., Guillaume, M., Kraan, M., Keung, A., Caceres, M., Boutros, T. The pharmacokinetics of SCH 417690 when administered alone end in combination with lamivudine/zidovudine. 6th Int Workshop Clin Pharmacol HIV Ther (April 28-30, Quebec) 2005, Abst 84.
50. Sansone, A., Keung, A., Tetteh, E. et al. Vicriviroc (VCV) pharmacokinetics (PK): Lack of impact of ritonavir (RTV)-boost ed protesse inhibitors (PI). 16th Int AIDS Conf (Aug 13-18, Toronto) 2006, Abst TuPe0074.
51. Sansone, A., Keung, A., Tetteh, E. et al. Pharmacokinetics of vicriviroc are not affected in combination with five different protease inhibitors boosted by ritonavir. 13th Conf Retroviruses Opportunistic Infect (CROI) (Feb 5-9, Denver) 2006, Abst 582.